Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development

Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species

(2018) Chen-chun Zhong et al.   ACTA PHARMACOLOGICA SINICA

Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

(2018) P G Casali et al.   ANNALS OF ONCOLOGY

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

(2018) Baohui Han et al.   BRITISH JOURNAL OF CANCER

Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor

(2018) Chengying Xie et al.   CANCER SCIENCE

Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1

(2018) Binyan Lin et al.   GENE

Kinase inhibitors: the road ahead

(2018) Fleur M. Ferguson et al.   NATURE REVIEWS DRUG DISCOVERY

Efficiency of anlotinib hydrochloride as 3rd line treatment in patients (pts) from a randomized, double-blind, placebo-controlled phase III trial, an exploratory subgroup analysis of ALTER0303 trial for the previous therapy strategy effect.

(2018) Qiming Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

OS outcomes to anlotinib in patients (pts) with refractory NSCLC of both wild-type (WT) and mutant EGFR.

(2018) Kai Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Subgroup analysis of elderly patients (pts) in ALTER0303: Anlotinib hydrochloride as 3rd-line and further line treatment in refractory advanced NSCLC pts from a randomized, double-blind, placebo-controlled phase III ALTER0303 trial.

(2018) Jianhua Shi et al.   JOURNAL OF CLINICAL ONCOLOGY

Anlotinib for metastasis soft tissue sarcoma: A randomized, double-blind, placebo-controlled and multi-centered clinical trial.

(2018) Yihebali Chi et al.   JOURNAL OF CLINICAL ONCOLOGY

Subgroup analysis of histology in ALTER0303: Anlotinib hydrochloride as 3rd line and further line treatment in refractory advanced NSCLC patients (pts).

(2018) Ying Cheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

(2017) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

P3.01-084 Analysis on ALTER0303 Trial: aCECs Level May Correlate with Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC

(2017) Z. Liu et al.   Journal of Thoracic Oncology

P3.03-006 Efficiency of Anlotinib as 3rd Line Treatment in Patients with Different EGFR Gene Status, an Exploratory Subgroup Analysis of ALTER0303 Trial

(2017) B. Han et al.   Journal of Thoracic Oncology

P3.03-017 Blood Samples NGS for Baseline Molecular Signature of Anotinib Treated Advanced NSCLC Patients in ALTER0303 Trial

(2017) B. Han et al.   Journal of Thoracic Oncology

Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors

(2016) Yongkun Sun et al.   Journal of Hematology & Oncology

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma

(2016) Robert J Motzer et al.   LANCET ONCOLOGY

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

(2016) Paul E. Hughes et al.   TRENDS IN IMMUNOLOGY

Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jin Li et al.   LANCET ONCOLOGY

Risk of arterial thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: An up-to-date meta-analysis

(2014) Wei-Xiang Qi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies

(2014) Mohammad Hojjat-Farsangi   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

(2014) Marcia S Brose et al.   LANCET

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO)

(2013) T. Valentin et al.   INVESTIGATIONAL NEW DRUGS

Cabozantinib in Progressive Medullary Thyroid Cancer

(2013) Rossella Elisei et al.   JOURNAL OF CLINICAL ONCOLOGY

Management of sarcoma in the Asia-Pacific region: resource-stratified guidelines

(2013) Jeremy Lewin et al.   LANCET ONCOLOGY

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

(2013) Thomas E Hutson et al.   LANCET ONCOLOGY

Sunitinib malate in solitary fibrous tumor (SFT)

(2012) S. Stacchiotti et al.   ANNALS OF ONCOLOGY

An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas

(2012) M. Agulnik et al.   ANNALS OF ONCOLOGY

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect

(2011) S. Stacchiotti et al.   ANNALS OF ONCOLOGY

Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings

(2011) J. Beck et al.   ANNALS OF ONCOLOGY

Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis

(2011) Philippe A. Cassier et al.   CANCER

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

(2010) Walter M. Stadler et al.   CANCER

Phase II Study of Daily Sunitinib in FDG-PET-Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

(2010) L. L. Carr et al.   CLINICAL CANCER RESEARCH

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study

(2010) Keith C Bible et al.   LANCET ONCOLOGY

Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor

(2010) James E. Butrynski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical pharmacokinetics of tyrosine kinase inhibitors

(2009) Nielka P. van Erp et al.   CANCER TREATMENT REVIEWS

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

(2009) Martin E Gore et al.   LANCET ONCOLOGY